Cmtx Biotech Inc.
Kings Park, NY
- UEI
- SQJJQU7ZLMB9
- CAGE
- 89E03
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 34 Black Gum Tree Ln, Kings Park, NY 11754, USA
- Website
- cmtxbiotech.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Cmtx Biotech Inc.
Cmtx Biotech Inc. is a drug development company focused on commercializing proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for treating diseases with high unmet medical needs. The company specializes in developing pleiotropic matrix metalloproteinase (MMP) modulators that inhibit excessive collagenolysis and resolve systemic inflammation. Registered in SAM.gov since February 2019, Cmtx Biotech operates as a for-profit corporate entity that has demonstrated capability in advancing innovative therapeutic solutions across multiple complex medical domains.
The company has secured multiple federal grant awards from civilian agencies, particularly from the National Institutes of Health, focusing on developing medical countermeasures and treatments for critical medical conditions. Their federal grant portfolio includes projects addressing sulfur mustard-induced lung injury (NIH, $299,993), bronchopulmonary dysplasia prevention in preterm infants (National Institute of Child Health and Human Development), acute respiratory distress syndrome (National Heart Lung and Blood Institute), and COVID-19 treatment (National Center for Advancing Translational Sciences). These grants, ranging from project grants to cooperative agreements, support preclinical and clinical research stages for their lead drug candidate Incyclinide (CMT-3/COL-3). The research spans diverse therapeutic areas, including chemical warfare injury countermeasures, pediatric respiratory disease prevention, sepsis-related acute respiratory complications, and viral infection management, demonstrating the company's versatile approach to developing host-directed therapeutics with potential broad medical applications.
Quick answers
What is Cmtx Biotech Inc.'s UEI?
Cmtx Biotech Inc.'s Unique Entity ID (UEI) in SAM.gov is SQJJQU7ZLMB9.
What is Cmtx Biotech Inc.'s CAGE code?
Cmtx Biotech Inc.'s CAGE code is 89E03.
What is Cmtx Biotech Inc.'s primary NAICS code?
Cmtx Biotech Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Cmtx Biotech Inc. located?
Cmtx Biotech Inc.'s physical address in SAM.gov is 34 Black Gum Tree Ln, Kings Park, NY 11754, USA.
Is Cmtx Biotech Inc. registered in SAM.gov?
Yes. Cmtx Biotech Inc.'s SAM.gov registration is active through March 16, 2027.
What is Cmtx Biotech Inc.'s most recent federal award?
Cmtx Biotech Inc.'s most recent federal grant award is A lung-specific, sulfonium lipid nanoparticle (slnp) formulation of incyclinide for the treatment of ALI/ards -… (R41HL184801), from National Heart Lung and Blood Institute, on September 1, 2026.
On GovTribe
See Cmtx Biotech Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors